CD3D
Overview
CD3D encodes the CD3 delta chain, a component of the CD3 complex that associates with the T-cell receptor (TCR) alpha/beta or gamma/delta chains to form the functional TCR-CD3 complex. The CD3 chains (CD3D, CD3E, CD3G, CD247/CD3Z) transduce activation signals from the TCR into the T cell upon antigen engagement. Expression of CD3D is a marker of T-cell infiltration in tumors.
Alterations observed in the corpus
- CD3D was identified as a component of the TCR/co-stimulatory immunological synapse upregulated on-therapy in melanoma patients receiving nivolumab (anti-PD-1). CD3D upregulation was part of a 695-gene differentially expressed gene set enriched in the genomic-contraction phenotype (q < 0.10) and a broader 475-DEG pharmacologic on-therapy response set (q < 0.20), encompassing PD-1 signaling, CD28 co-stimulation, downstream TCR signaling, IFN-gamma, and IL-2 signaling. PMID:29033130
Cancer types (linked)
- SKCM: CD3D on-therapy upregulation in melanoma patients on nivolumab marks T-cell infiltration and activation within the tumor, correlating with the genomic-contraction phenotype that predicted superior survival in independent immunotherapy cohorts. PMID:29033130
Co-occurrence and mutual exclusivity
Therapeutic relevance
- On-therapy induction of CD3D and the broader TCR-signaling gene program under anti-PD-1 therapy supports the mechanistic model that nivolumab restores productive T-cell activation and clonal expansion in the tumor microenvironment. PMID:29033130
Open questions
- Whether pre-therapy CD3D expression level is a predictive biomarker for anti-PD-1 response was not independently reported for CD3D specifically, though a broader “hot tumor” phenotype pre-therapy was associated with benefit in ipilimumab-progressed patients. PMID:29033130
Sources
This page was processed by crosslinker on 2026-05-15.